九安醫療盤初拉昇漲近8%:預計前三季淨利同比增318倍至324倍
格隆匯10月17日丨九安醫療盤初拉昇漲近8%報50.59元,市值243億港元。九安醫療上週五晚公吿,預計前三季度淨利160億元-163億元,同比增31818.29%至32416.76%。報吿期內受疫情影響,公司的iHealth試劑盒產品在美國市場需求旺盛,公司業績較去年同期大幅增長;美元匯率持續走高,公司匯兑收益較去年同期增加。九安醫療Q2淨利9.32億元,據此計算,預計Q3淨利7.56億元-10.56億元,環比變動-19%至13%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.